Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pirinase Allergy 0.05% Nasal Spray
⚠ This medicine appears to have been discontinued
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Fluticasone propionate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
What it is and what it is used for
for
Pirinase Allergy is used to treat and prevent the allergic symptoms of hayfever and other airborne allergies e.g. pet, house dust mite and mould spore allergies. It relieves symptoms including sneezing, itchy and watery eyes and a runny, itchy or blocked-up nose, for up to 24 hours. The active ingredient is fluticasone propionate, a corticosteroid which, when used every day, has an anti-inflammatory action and works in a similar way to natural body chemicals to control inflammation. This spray helps to control your body's reactions to allergens ('triggers') in the environment.
Take special care with Pirinase Allergy
- Talk to your doctor or pharmacist before using Pirinase Allergy if you have an infection in your nose or sinuses, if you have a high temperature or you have recently had surgery, an injury or ulcers in your nose.
- If your symptoms do not improve, or are not well controlled, after 7 days, talk to your doctor or pharmacist.
- This medicine should not be used for more than 3 months continuously without consulting a doctor.
- When corticosteroid nasal sprays are used at high doses for long periods of time, side effects may occur due to the drug being absorbed in the body.
- Stop taking this medicine and tell your doctor if you experience any psychological or behavioural problems such as psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression.
- Contact your doctor if you experience blurred vision or other visual disturbances, which could be caused by conditions such as cataract or glaucoma.
- Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription; particularly corticosteroid medicines (including eczema creams, asthma inhalers, tablets, injections, nasal sprays, and eye or nose drops).
If you are taking other medicines
- Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription; particularly corticosteroid medicines (including eczema creams, asthma inhalers, tablets, injections, nasal sprays, and eye or nose drops).
- Do not use this medicine if you are taking medicines for HIV (e.g. ritonavir or cobicistat) or for fungal infections (e.g. ketoconazole).
- Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including erythromycin (for bacterial infections).
Always shake gently before use. Only use in the nose. Do not swallow. Pirinase Allergy quickly starts to reduce inflammation and swelling in your nose, although it may take 3 or 4 days to build up to its maximum protective effect. To prevent the onset of symptoms, start to use Pirinase Allergy before exposure to one of your usual 'triggers'. You should try to use the spray in the morning. Adults and adolescents aged 12 years and over: Spray two puffs into each nostril once daily. Once your symptoms have improved, you may be able to reduce the dose to one puff into each nostril once daily. If your symptoms are especially bad, you may need to spray two puffs into each nostril twice daily until your symptoms improve.
- Do not use more than 4 sprays in each nostril in a day.
- Use the lowest dose possible to control your symptoms.
- If your symptoms do not improve, or are not well controlled, after 7 days, talk to your doctor or pharmacist.
- This medicine should not be used for more than 3 months continuously without consulting a doctor.
- Do not use more than the recommended dose.
If you use too many sprays Tell your doctor.
If you forget to use the spray
Take your next dose at the usual time. Never take two doses together.
Before using a new bottle of Pirinase Allergy:
- Your Pirinase Allergy spray has a dust cap which protects the nozzle and keeps it clean. Remember to take it off before you use the spray (Picture 1).
- Before you start to use a new bottle of Pirinase Allergy, or if you have not used the spray for a few days, press the pump down several times until you get a fine spray.
- Hold the bottle as shown with your forefinger and middle finger on the collar either side of the nozzle and your thumb underneath the bottle. 2
1
Pregnancy and breast feeding Talk to your doctor before using Pirinase Allergy if you are pregnant, trying to become pregnant or are breast feeding. 62000000097639
TECHNICAL INFORMATION CUT
TEXT AND GRAPHIC FREE AREA
BLACK SPOT / EYE MARK Colour Black or according to colour used in the final brief
LAETUS CODE
0 1
Replaced dwg n.70 Drawing revision
DRAWING OWNER (SITE)
Aranda
Simple Leaflet Reel 304 x 180 PACKAGING MATERIAL DRAWING REGIONAL SERVICE CENTRE, VERONA
COPYRIGHT AND DESIGN RIGHT IS THE PROPERTY OF THE GLAXOSMITHKLINE GROUP OF COMPANIES
SCALE: NOT IN SCALE
GENERAL TOLERANCE UNLESS OTHERWISE STATED
ALL DIMS. IN MILLIMETRES
±1 mm
V5
On back side
18 – Nov – 2025
FOLDING MAP
Approving Market: Great Britain 70%
1.
50%
Black
Material Spec No: ESPT-PR-02 (Note: North American Artwork will have N/A in this field)
Body Text Size: 7.5pt Smallest Text Size: 7.5pt (Note: For North American Artwork, see Regulatory Spec box for this information)
Electronic Verification Code: 9298
Total Special Finishes:
Studio Location: AIP_CHAMPS_2023_HALEON
180
Technical Drawing No: 02-01-XX-273-02
20%
0
Europe
Printer and User notes: N/A
1° Fold 1/2
2° Fold 1/3
3° Fold 1/2
4° Fold 1/2
Folded leaflet
BARCODE INFO Barcode Type Barcode Number: Magnification: BWR:
Pharmacode Standard 9298 100 0 Micrometre
FRONT
TEXT DIRECTION
On back side
Folding when carton dimension "A" bigger than 50 mm
Pharmacode Standard 9298 100 0 Micrometre
BARCODE INFO Barcode Type Barcode Number: Magnification: BWR:
TEXT DIRECTION
180
Folding when carton dimension "A" smaller than 50 mm
(Note: North American Artwork will have N/A in this field)
TEXT DIRECTION
62000000097639 TR3390396/E Manufacturing Site: Aranda, Spain
27
X
TEXT DIRECTION
1
180 1° Fold 1/2
2° Fold 1/2
Ø 70
3° Fold 1/2
Folded leaflet
40
Production Artwork
Ø 600 max.
MATERIAL as per related Technical Specification
Leading direction
Non Production Artwork Total Number of Colours including Varnish & Foils:
Component No: AWP No:
- Keeping your thumb still, press down with your fingers to pump the spray (Picture 2).
- When doing this make sure you do not point the nozzle at yourself or someone else.
- If the spray still doesn't work, try to clean it as described under the 'To clean the spray' section. Do not try to unblock or enlarge the tiny spray hole with a pin or other sharp objects because this will destroy the spray mechanism.
6. Remove the nozzle from this nostril and breathe out through your mouth (Picture 5). 7. Repeat steps 3 to 6 for the other nostril. 8. After using the spray, wipe the nozzle carefully with a clean tissue or handkerchief and replace the dust cap.
To clean the spray: 1. Take the dust cap and nozzle off (Picture 6).
Using Pirinase Allergy: 1. Shake the bottle gently and remove the dust cap. 2. Blow your nose gently. 3. Close one nostril as shown and put the nozzle in the other nostril. Tilt your head forward slightly and keep the bottle upright. Hold the bottle as shown (Picture 3). 4. Start to breathe in slowly through your nose. While you are breathing in, squirt a spray of fine mist into your nostril by pressing down firmly on the collar with your fingers (Picture 4). 5. Breathe out through your mouth. Repeat step 4 to take a second spray in the same nostril, if required.
2. Soak the nozzle and dust cap in warm water for a few minutes and then rinse under a running tap.
Common (may affect up to 1 in 10 people)
- Headache.
- Unpleasant taste or smell.
- Dryness or irritation in the nose or throat. Unknown (frequency cannot be estimated from the available data)
- Eye problems such as blurred vision.
- Sores in the nose. Other side effects which have been reported are:
- Sneezing after using the spray but this soon stops. It is important to follow the dose instructions shown in Section 3. Using Pirinase Allergy at higher doses or for longer than 3 months at a time can cause a number of changes in your body such as catching infections more easily.
6
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
How to take it
Pirinase Allergy 4. Possible side effects 5. How to store Pirinase Allergy 6. Contents of the pack and other information
Possible side effects
5
Like all medicines, Pirinase Allergy can have side effects, but not everybody gets them. Stop taking this medicine and seek immediate medical help if you experience: Very rare (may affect up to 1 in 10,000 people)
- Allergic reactions. These may include developing a rash, swelling of the mouth or face or having difficulty breathing.
- Psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children).
- Damage to your nose.
- Increased pressure in the eye (glaucoma).
- Cloudy lens in the eye (cataract). Stop taking this medicine and tell your doctor if you experience:
- Eye problems such as pain.
- Nasal problems such as pain and/or persistent bleeding.
How to store it
Pirinase Allergy
Keep out of the sight and reach of children. Do not use this medicine after the 'EXP' date shown on the pack. Use within three months of first use. Do not store above 30°C.
4
3
3. Shake off the excess water and allow to dry in a warm place – not too hot! 4. Re-fit the nozzle. 5. If necessary, press the pump down several times until you get a fine spray.
Contents of the pack and other information
Active ingredient Each spray contains Fluticasone Propionate 50 micrograms. Other ingredients Dextrose (anhydrous), microcrystalline cellulose, carboxymethylcellulose sodium, phenylethyl alcohol, benzalkonium chloride, polysorbate 80, purified water and dilute hydrochloric acid. The bottle contains 60 or 120 sprays. The marketing authorisation holder is Haleon UK Trading Limited, The Heights, Weybridge, KT13 0NY, U.K. and all enquiries should be sent to this address. The manufacturer is Glaxo Wellcome SA, 09400 Aranda de Duero, Burgos, Spain. This leaflet was last revised in November 2025. This information in this leaflet only applies to Pirinase Allergy 0.05% Nasal Spray. Trade Marks are owned by or licensed to the Haleon group of companies.
Very common (may affect more than 1 in 10 people)
- Nose bleeds.
62000000097639
TECHNICAL INFORMATION CUT
TEXT AND GRAPHIC FREE AREA
BLACK SPOT / EYE MARK Colour Black or according to colour used in the final brief
LAETUS CODE
0 1
Replaced dwg n.70 Drawing revision
DRAWING OWNER (SITE)
Aranda
Simple Leaflet Reel 304 x 180 PACKAGING MATERIAL DRAWING REGIONAL SERVICE CENTRE, VERONA
COPYRIGHT AND DESIGN RIGHT IS THE PROPERTY OF THE GLAXOSMITHKLINE GROUP OF COMPANIES
SCALE: NOT IN SCALE
GENERAL TOLERANCE UNLESS OTHERWISE STATED
ALL DIMS. IN MILLIMETRES
±1 mm
V5
On back side
18 – Nov – 2025
FOLDING MAP
Approving Market: Great Britain 70%
1.
50%
Black
Material Spec No: ESPT-PR-02 (Note: North American Artwork will have N/A in this field)
Body Text Size: 7.5pt Smallest Text Size: 7.5pt (Note: For North American Artwork, see Regulatory Spec box for this information)
Electronic Verification Code: 9298
Total Special Finishes:
Studio Location: AIP_CHAMPS_2023_HALEON
180
Technical Drawing No: 02-01-XX-273-02
20%
0
Europe
Printer and User notes: N/A
1° Fold 1/2
2° Fold 1/3
3° Fold 1/2
4° Fold 1/2
Folded leaflet
BARCODE INFO Barcode Type Barcode Number: Magnification: BWR:
Pharmacode Standard 9298 100 0 Micrometre
FRONT
TEXT DIRECTION
On back side
Folding when carton dimension "A" bigger than 50 mm
Pharmacode Standard 9298 100 0 Micrometre
BARCODE INFO Barcode Type Barcode Number: Magnification: BWR:
TEXT DIRECTION
180
Folding when carton dimension "A" smaller than 50 mm
(Note: North American Artwork will have N/A in this field)
TEXT DIRECTION
62000000097639 TR3390396/E Manufacturing Site: Aranda, Spain
27
X
TEXT DIRECTION
1
180 1° Fold 1/2
2° Fold 1/2
Ø 70
3° Fold 1/2
Folded leaflet
40
Production Artwork
Ø 600 max.
MATERIAL as per related Technical Specification
Leading direction
Non Production Artwork Total Number of Colours including Varnish & Foils:
Component No: AWP No:
Frequently asked questions about Pirinase Allergy 0.05% Nasal Spray
How do I take Pirinase Allergy 0.05% Nasal Spray?
Pirinase Allergy 0.05% Nasal Spray comes as nasal spray. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
What is the active substance in Pirinase Allergy 0.05% Nasal Spray?
The active substance in Pirinase Allergy 0.05% Nasal Spray is fluticasone propionate.
Are there equivalent medicines to Pirinase Allergy 0.05% Nasal Spray?
Medicines with the same active substance, strength and form include: Flixonase Aqueous Nasal Spray, Pirinase Hayfever Once Daily 0.05% Nasal Spray. They are interchangeable only if your prescriber or pharmacist says so.
Where does this information come from?
This leaflet reproduces the patient information leaflet approved for Pirinase Allergy 0.05% Nasal Spray, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Can I get Pirinase Allergy 0.05% Nasal Spray without a prescription?
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
About this leaflet
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Source: electronic medicines compendium (emc), Datapharm
- Active substance: fluticasone propionate
- Official document: view the original leaflet on emc →
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
4.1. Therapeutic indications
For the prophylaxis and treatment of allergic rhinitis including hay fever and that caused by other airborne allergens such as house dust mite and animal dander.
This medicine also provides symptomatic relief of sneezing, itchy and runny nose, itchy and watery eyes, nasal congestion and associated sinus discomfort.
4.2. Posology and method of administration
For administration by the intranasal route only.
Adults and adolescents aged 12 years and over: For the prophylaxis and treatment of allergic rhinitis:
Two sprays into each nostril once a day, preferably in the morning. In some cases two sprays into each nostril twice daily may be required. Once symptoms are under control a maintenance dose of one spray per nostril once a day may be used. If symptoms recur the dosage may be increased accordingly. The minimum dose at which effective control of symptoms is maintained should be used.
The maximum daily dose should not exceed four sprays into each nostril.
Elderly: The normal adult dosage is applicable.
Children under 12 years of age: Should not be used by children and adolescents under 12 years of age.
Prophylaxis of allergic rhinitis requires treatment before contact with allergen. For full therapeutic benefit regular usage is recommended.
Maximum benefit may require 3-4 days of continuous treatment in some people (see section 5.1, Pharmacodynamic Properties).
Shake gently before use.
Before use the bottle needs to be primed by pumping until a fine spray is produced.
4.3. Contraindications
Hypersensitivity to fluticasone propionate or any other of the ingredients.
Concomitant use with HIV medicines.
4.4. Special warnings and precautions for use
Treatment should be stopped or the advice of a doctor sought if an improvement is not seen within 7 days. The advice of a doctor or pharmacist should also be sought if symptoms have improved but are not adequately controlled. This medicine should not be used for more than 3 months continuously without consulting a doctor.
Although fluticasone propionate aqueous nasal spray will control seasonal allergic rhinitis in most cases, an abnormally heavy challenge of summer allergens may in certain instances necessitate appropriate additional therapy.
Medical advice should be sought before using this medicine in the case of;
o concomitant use of other corticosteroid products, such as tablets, creams, ointments, asthma medications, similar nasal sprays or eye/nose drops
o fever or an infection in the nasal passages or sinuses.
o recent injury or surgery to the nose, or problems with ulceration in the nose.
Local infection: infections of the nasal airways should be appropriately treated but do not constitute a specific contraindication to treatment with intranasal fluticasone propionate.
Care must be taken when withdrawing patients from systemic steroid treatment, and commencing therapy with intranasal fluticasone propionate, particularly if there is any reason to suspect that their adrenal function is impaired.
Treatment with higher than recommended doses of nasal corticosteroids may result in clinically significant adrenal suppression. If there is evidence of higher than recommended doses being used then additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.
Significant interactions between fluticasone propionate and potent inhibitors of the cytochrome P450 3A4 system, e.g. ketoconazole and protease inhibitors, such as ritonavir and cobicistat, may occur. This may result in increased systemic exposure to fluticasone propionate.
Systemic effects of nasal corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids and may vary in individual patients and between different corticosteroid preparations. Potential systemic effects may include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataract, glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children).
Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
Contains Benzalkonium Chloride which may cause bronchospasm.
4.5. Interaction with other medicinal products and other forms of interaction
Under normal circumstances, low plasma concentrations of fluticasone propionate are achieved after intranasal dosing, due to extensive first pass metabolism and high systemic clearance mediated by cytochrome P450 3A4 in the gut and liver. Hence, clinically significant drug interactions mediated by fluticasone propionate are unlikely.
Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side-effects.
In an interaction study in healthy subjects with intranasal fluticasone propionate, ritonavir (a highly potent cytochrome P450 3A4 inhibitor) 100 mg b.i.d. increased the fluticasone propionate plasma concentrations several hundred fold, resulting in markedly reduced serum cortisol concentrations. Cases of Cushing's syndrome and adrenal suppression have been reported. The combination should be avoided unless the benefit outweighs the increased risk of systemic glucocorticoid side-effects.
Other inhibitors of cytochrome P450 3A4 produce negligible (erythromycin) and minor (ketoconazole) increases in systemic exposure to fluticasone propionate without notable reductions in serum cortisol concentrations. Care is advised when co-administering cytochrome P450 3A4 inhibitors, especially in long-term use and in case of potent inhibitors, as there is potential for increased systemic exposure to fluticasone propionate.
4.6. Fertility, pregnancy and lactation
There is inadequate evidence of the safety of fluticasone propionate in human pregnancy. Administration of corticosteroids to pregnant animals can cause abnormalities of foetal development, including cleft palate and intra-uterine growth retardation. There may therefore be a very small risk of such effects in the human foetus. It should be noted however that the foetal changes in animals occur after relatively high systemic exposure; direct intranasal application ensures minimal systemic exposure. As with other drugs the use of this medicine during human pregnancy requires that the possible benefits of the drug be weighed against the possible hazards.
The secretion of fluticasone propionate in human breast milk has not been investigated. Subcutaneous administration of fluticasone propionate to lactating laboratory rats produced measurable plasma levels and evidence of fluticasone propionate in milk. However, following intranasal administration to primates, no drug was detected in the plasma, and it is therefore unlikely that the drug would be detectable in milk. When this medicine is used in breast feeding mothers the therapeutic benefits must be weighed against the potential hazards to mother and baby.
The label will include a warning that medical opinion should be sought, before using this medicine, in the case of pregnancy or breast feeding.
4.7. Effects on ability to drive and use machines
None reported.
4.8. Undesirable effects
Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (>1/10), common (>1/100 and <1/10), uncommon (>1/1000 and <1/100), rare (>1/10,000 and <1/1000) and very rare (<1/10,000) including isolated reports. Very common, common and uncommon events were generally determined from clinical trial data. Rare and very rare events were generally determined from spontaneous data. In assigning adverse event frequencies, the background rates in placebo groups were not taken into account.
System Organ Class
Adverse Event
Frequency
Immune system disorders
Hypersensitivity reactions, anaphylaxis/anaphylactic reactions, bronchospasm, skin rash, oedema of the face or tongue
Very rare
Nervous system, disorders
Headache, unpleasant taste, unpleasant smell
Common
Eye disorders
Glaucoma, raised intraocular pressure, cataract
Very rare
Blurred Vision
Unknown
Respiratory, thoracic and mediastinal disorders
Epistaxis
Very common
Nasal dryness, nasal irritation, throat dryness, throat irritation
Common
Nasal septal perforation
Very rare
Nasal Ulcers
Unknown
As with other nasal sprays, dryness and irritation of the nose and throat, unpleasant taste and smell, headache and epistaxis have been reported.
Nasal ulceration and nasal septal perforation have been reported following the use of intranasal corticosteroids, usually when there has been previous nasal surgery.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9. Overdose
Administration of doses higher than those recommended over a long period of time may lead to temporary suppression of adrenal function.
There are no data available on the effects of acute or chronic overdosage with this medicine. Intranasal administration of fluticasone propionate at 20 times the recommended starting dose in adults (2mg twice daily) for seven days to healthy human volunteers had no effect on hypothalamic-pituitary-adrenal axis function.
💬 Ask about this leaflet
Ask anything about Pirinase Allergy 0.05% Nasal Spray. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
Medicines containing Fluticasone propionate
- Cutivate Cream 0.05%
- Cutivate Ointment 0.005%
- Flixonase Aqueous Nasal Spray
- Flixotide 125 micrograms Evohaler
- Flixotide 250 micrograms Evohaler
- Flixotide 50 micrograms Evohaler
- Flixotide Accuhaler
- Fluticasone Propionate 0.05% cream
- Fluticasone propionate 400 micrograms (1mg/ml), nasal drops suspension
- Pirinase Hayfever Once Daily 0.05% Nasal Spray